Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab versus standard chemotherapy consolidation in pediatric high-risk first-relapse B-cell precursor acute lymphoblastic leukemia
MOH_2017-11-14_000808Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Jul 2015
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of blinatumomab in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Amgen. Started Jul 2015; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on MOH_2017-11-14_000808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-11-14_000808.